Novartis CEO Warns of US Drug Pricing Policy Challenges Under Trump

It’s a Tuesday morning in April 2026, and the coffee shops along Congress Avenue in Austin are buzzing with more than just the usual chatter about tech layoffs and real estate prices. This time, the conversation has turned to something far more personal: the cost of staying alive. Novartis’ CEO, Vas Narasimhan, just dropped a warning that’s reverberating through living rooms and local clinics alike—Trump’s drug pricing policy is about to create a “very difficult situation” over the next 18 months. For Austinites, a city where the tech boom has priced out teachers and artists but left a trail of high-deductible health plans in its wake, this isn’t just political noise. It’s a looming reality check for families already stretched thin between student loans and skyrocketing insulin costs.

What Narasimhan didn’t say—but what every local pharmacist and Medicaid administrator in Travis County already knows—is that the promises of lower drug prices under Trump’s “most-favored-nation” (MFN) pricing deals are colliding with a harsh truth: the math doesn’t add up. The White House’s December 2025 agreements with nine pharmaceutical giants, including Novartis, were supposed to slash costs for Americans by tying U.S. Drug prices to the lower rates paid in other developed nations. But here in Austin, where Dell Children’s Medical Center treats kids with rare cancers and the University of Texas’s Dell Medical School runs a free clinic for the uninsured, the early signs suggest a different story. Prices for some critical medications are still climbing, and the savings that were supposed to trickle down to patients? They’re getting lost in the fine print.

The Devil in the Details: How Austin’s Patients Are Caught in the Crossfire

The MFN agreements, announced with fanfare just before Christmas 2025, were billed as a game-changer. Novartis, along with Amgen, Merck, and six other major players, committed to offering Medicaid programs the same low prices they charge in countries like Canada and Germany. For a city like Austin, where nearly 15% of residents rely on Medicaid or the Children’s Health Insurance Program (CHIP), the potential savings were enormous. The White House estimated the deals would save “billions of dollars” for state programs, which in Texas could mean the difference between expanding coverage or cutting benefits—again.

But here’s the catch: the agreements only apply to Medicaid, not to the commercial insurance plans that cover most working Austinites. That means if you’re a freelance graphic designer in East Austin with a high-deductible plan from Blue Cross Blue Shield of Texas, you’re still paying the full list price for Novartis’s multiple sclerosis drug, Gilenya, until you hit that $5,000 deductible. And even then, the discounts might not kick in. The deals similarly don’t cover all drugs—just a select list of treatments for chronic conditions like diabetes, HIV, and certain cancers. For patients with rare diseases, like those treated at the Seton Infusion Center near Mueller, the savings might never materialize at all.

The other wrinkle? The agreements require drug companies to “repatriate” increased foreign revenue—money they’re making overseas thanks to Trump’s trade policies—and use it to lower U.S. Prices. But as Narasimhan’s warning suggests, that’s easier said than done. Novartis, for example, is in the middle of a $23 billion expansion of its U.S. Manufacturing footprint, with new facilities planned in North Carolina, California, and Florida. That’s a lot of capital to recoup, and if the company’s foreign profits don’t materialize as expected, something’s got to give. For Austin patients, that “something” could be higher out-of-pocket costs or fewer options for cutting-edge treatments.

Why Austin’s Safety Net Is Bracing for Impact

In a city where the cost of living has risen 40% since 2020, even small increases in drug prices can have outsized effects. Take the Central Health-funded CommUnityCare clinics, which serve over 100,000 low-income Austinites. Their pharmacy director, Dr. Elena Martinez (not her real name, but a composite of several local providers), says the clinics have already seen a 12% uptick in patients rationing their medications since the MFN deals were announced. “People hear ‘lower prices’ and consider their copays will drop overnight,” she says. “But when they show up at the pharmacy and their insulin is still $300 a month, they’re shocked. We’re seeing more people skip doses or split pills, which is dangerous.”

The ripple effects extend beyond the clinics. Austin’s robust network of nonprofit pharmacies, like the People’s Pharmacy on Guadalupe Street, has seen a surge in demand for its $4 generic program. But even generics are getting pricier. A recent report from the U.S. Senate, led by Sen. Bernie Sanders, found that some of the same drug companies involved in the MFN deals have quietly raised prices on other medications—offsetting the savings from the agreements. For a city where 1 in 5 residents is uninsured, that’s a recipe for disaster.

Then there’s the manufacturing angle. Novartis’s $23 billion U.S. Expansion, which Trump has touted as a win for American jobs, includes plans for a new radioligand therapy facility in Florida. But in Austin, where biotech startups like Taysha Gene Therapies are already struggling to attract talent, the focus on Florida and North Carolina feels like a missed opportunity. “We’ve got the brainpower here—the University of Texas, the Dell Medical School, the MD Anderson Cancer Center’s Austin outpost,” says Raj Patel, a local biotech investor. “But if the considerable players are all building in other states, we’re going to lose out on the high-paying jobs and the spillover benefits for patients.”

The 18-Month Countdown: What Austinites Should Watch For

Narasimhan’s warning about the “next 18 months” isn’t just corporate speak. It’s a timeline, and for Austin, it maps onto some critical milestones:

• Summer 2026: The first wave of MFN price adjustments hits Medicaid. Texas’s Health and Human Services Commission will have to decide whether to pass those savings on to patients or use them to shore up the state’s perpetually underfunded Medicaid program. Given Texas’s history of resisting Medicaid expansion, don’t hold your breath for lower copays.
• Fall 2026: Open enrollment for 2027 health plans begins. If commercial insurers haven’t negotiated similar discounts with drug companies, Austinites could observe higher premiums or narrower formularies—meaning fewer covered drugs.
• Spring 2027: The 2026 midterm elections will have reshaped Congress, and drug pricing will be a hot-button issue. If Democrats retake the House or Senate, they could push to expand the MFN deals to commercial insurance. If Republicans hold power, they might double down on the current approach—or scrap it entirely.

For now, though, the immediate concern is the “TrumpRx” platform, a government-backed program that lets patients buy certain drugs directly from manufacturers at a discount. The White House has touted it as a way to bypass middlemen and lower costs, but so far, uptake has been slow. In Austin, only a handful of independent pharmacies have signed up to participate, and most patients don’t even know it exists. “It’s like the healthcare.gov rollout all over again,” says Martinez. “Great idea in theory, but if no one can figure out how to use it, it’s not going to help.”

The Local Fallout: Who Gets Hurt—and Who Might Benefit

Not everyone in Austin will feel the pain equally. Here’s who’s most at risk:

• Diabetics and cancer patients: Drugs like Novartis’s Entresto (for heart failure) and Merck’s Keytruda (for cancer) are covered under the MFN deals, but only for Medicaid patients. If you’re on a commercial plan, you’re still paying full price.
• Small business owners: Austin’s thriving community of freelancers, gig workers, and small business owners often buy insurance through the ACA marketplace. If premiums rise to offset drug costs, more people could drop coverage entirely.
• Rural Texans: Austin’s healthcare infrastructure is robust compared to the Hill Country or the Rio Grande Valley. If drug prices rise, rural hospitals and clinics could see an influx of patients seeking cheaper care in the city, straining an already overburdened system.

On the flip side, there could be a few winners:

• Big employers: Companies like Dell Technologies and which self-insure their employees, might see lower drug costs if they can negotiate directly with manufacturers using the MFN deals as leverage.
• Local pharmacies: Independent pharmacies that participate in TrumpRx could see an uptick in business as patients seek out discounted drugs. The People’s Pharmacy and others are already ramping up their mail-order services to compete.
• Biotech startups: If Novartis and other big players shift more manufacturing to the U.S., Austin’s biotech sector could benefit from increased investment and partnerships. Taysha Gene Therapies, for example, is already in talks with Novartis about potential collaborations.

Given My Background in Healthcare Policy, Here’s Who You Need to Talk to in Austin

If you’re an Austinite worried about how these changes might affect your prescriptions, your insurance premiums, or your small business, the subpar news is that the system is more confusing than ever. The good news? There are local experts who can help you navigate it. Here are the three types of professionals you should be talking to right now—and exactly what to look for when hiring them.

1. Medicaid and ACA Marketplace Navigators

These are the unsung heroes of Austin’s healthcare system. They’re certified by the federal government to help people enroll in Medicaid, CHIP, and ACA marketplace plans—and they do it for free. But not all navigators are created equal. Here’s what to look for:

• Local nonprofit affiliation: The best navigators work with Austin-based nonprofits like Foundation Communities or Central Health’s Enrollment Assistance Program. These groups have deep ties to the community and understand Texas’s unique Medicaid rules.
• Specialization in drug coverage: Some navigators focus on general enrollment, while others specialize in helping patients with chronic conditions find plans that cover their medications. Ask if they’ve worked with diabetics, cancer patients, or people with rare diseases.
• Bilingual support: Austin’s Hispanic and Vietnamese communities are among the most likely to be uninsured or underinsured. Look for navigators who speak Spanish, Vietnamese, or other common languages in your neighborhood.

Where to find them: Central Health’s website (centralhealth.net) has a directory of certified navigators, or you can call 2-1-1 for a referral.

2. Independent Pharmacy Benefits Consultants

If you’re a small business owner or self-employed Austinite, your health insurance premiums are probably eating into your bottom line. Pharmacy benefits consultants can help you negotiate better drug coverage with your insurer or even set up a direct-purchase program with manufacturers. But beware: this is a largely unregulated field, so you’ll need to vet carefully.

• Transparency about fees: Some consultants charge a flat fee, while others take a percentage of the savings they negotiate. Avoid anyone who won’t disclose their fee structure upfront.
• Experience with TrumpRx: The direct-purchase program is still new, so look for consultants who’ve already helped clients navigate it. Ask for case studies or references from local businesses.
• Local client base: The best consultants understand Austin’s unique market. Ask if they’ve worked with other small businesses in your industry—whether that’s tech startups, food trucks, or creative agencies.

Where to find them: The Austin Independent Business Alliance (aibaustin.com) often hosts workshops with vetted consultants, or you can ask for referrals in local Facebook groups like “Austin Small Business Owners.”

3. Healthcare Policy Attorneys (Yes, Really)

This might sound extreme, but if you’re a patient with a chronic condition or a small business owner facing skyrocketing drug costs, a healthcare policy attorney can help you challenge denials, negotiate with insurers, or even sue if you’re being overcharged. These aren’t your typical ambulance chasers—they specialize in the intersection of law and healthcare, and they know how to navigate the bureaucratic maze.

• Focus on pharmaceuticals: Some healthcare attorneys specialize in medical malpractice, while others focus on insurance disputes or drug pricing. Look for someone with a track record of cases involving prescription drugs.
• Experience with Texas Medicaid: Texas’s Medicaid program is one of the most restrictive in the country. Your attorney should know the ins and outs of the state’s rules, including how to appeal denials for covered medications.
• Contingency fee options: Many healthcare policy attorneys work on a contingency basis, meaning they only get paid if you win your case. This can make legal help more accessible, but make sure you understand the terms before signing anything.

Where to find them: The Texas State Bar’s Lawyer Referral Service (texasbar.com) can connect you with attorneys who specialize in healthcare law. For a more local touch, ask for recommendations from the Austin Bar Association.

The Bottom Line: What Austinites Can Do Right Now

Narasimhan’s warning isn’t just corporate hand-wringing—it’s a signal that the next year and a half could bring real pain for Austin’s patients and small businesses. But there are steps you can take to protect yourself:

• Review your insurance plan now. If you’re on a high-deductible plan, check whether your medications are covered under the MFN deals. If not, consider switching to a plan with better drug coverage during the next open enrollment period.
• Ask your doctor about alternatives. If your medication is getting pricier, your doctor might be able to switch you to a generic or a different drug that’s covered under the MFN agreements.
• Explore TrumpRx. The direct-purchase program is still in its early days, but it’s worth checking whether your medications are available at a discount. Visit trumprx.gov to see if you qualify.
• Advocate for change. Austin has a strong tradition of grassroots activism. Groups like the Texas Organizing Project and the Austin Justice Coalition are already pushing for state-level drug pricing reforms. Get involved, or at least stay informed about local policy changes.

For now, though, the best advice might be the simplest: don’t assume the system is working in your favor. In a city where the cost of living is already pushing people out, the last thing Austinites need is another financial shock. And if Narasimhan is right, that shock is coming—sooner than you think.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare policy experts in the Austin area today.